Multi-kinase-IN-7

Multi-kinase-IN-7 is a multikinase inhibitor with IC50s of 2.19, 2.95, 3.59 and 9.31 μM against EGFR, VEGFR2, TrKA and CDK2, respectively. Multi-kinase-IN-7 shows moderate and weaker activity against FAK, AKT1, GSK3β and CDK5 with IC50 values of 6.3, 9.2, 11.7 and 23.4 μM, respectively. Multi-kinase-IN-7 displays broad spectrum antiproliferative potential against NCI cancer cell lines. Multi-kinase-IN-7 induces cell cycle arrest, apoptosis and necrosis. Multi-kinase-IN-7 Inhibitor can be used for the study of breast cancer[1].

Product Specifications

UNSPSC

12352005

Target

Akt; Apoptosis; Bcl-2 Family; Caspase; CDK; EGFR; FAK; GSK-3; Trk Receptor; VEGFR

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; JAK/STAT Signaling; Neuronal Signaling; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Field of Research

Cancer

Smiles

N#CC1=C(N)N2C(NC1C3=CC=C(Br)C=C3)=NC(C4=CC=CC=C4)=N2

Molecular Formula

C18H13BrN6

Molecular Weight

393.24

References & Citations

[1]Eldeeb AH, et al. Design, synthesis and biological evaluation of triazolo[1,5-a]pyrimidine derivatives as new antiproliferative agents with multikinase inhibitory activity. Bioorg Chem. 2025 Aug 22;165:108899.